Sandbox 123456: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
==Introduction== | ==Introduction== | ||
Noxafil, also known as Posaconazole, was developed by Schering-Plough in the mid-2000s (acs.org), and is an antifungal drug used to treat fungal infections caused by Candida and Aspergillus species, as well as treat other fungal infections such as chromoblastomycosis, mycetoma, and coccidioidomycosis. Noxafil is also often used when other antifungal medicines are tolerated or if the patient is immunocompromised. Noxafil | Noxafil, also known as Posaconazole, was developed by Schering-Plough in the mid-2000s (acs.org), and is an antifungal drug used to treat fungal infections caused by Candida and Aspergillus species, as well as treat other fungal infections such as chromoblastomycosis, mycetoma, and coccidioidomycosis. Noxafil is also often used when other antifungal medicines are tolerated or if the patient is immunocompromised. Noxafil falls under the triazole class of antifungal drugs and thus works by inhibiting the production of ergosterol, an important factor in fungi cell membranes, leading to prevention of cell growth and ultimately death. | ||
==Structure== | ==Structure== | ||
| Line 8: | Line 8: | ||
*Molecular Weight: 700.792 g/mol | *Molecular Weight: 700.792 g/mol | ||
*IUPAC name: 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one | *IUPAC name: 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one | ||
The structure of Posaconazole allows it to | The structure of Posaconazole allows it to act as a potent, broad-spectrum antifungal drug that was derived from another triazole antifungal agent, Itraconazole. The differences in structure are that the Chlorine substituents in the aromatic ring on the left-hand side of the images are replaces with Fluorines and that the triazolone sidechain is hydroxylated in the Posaconazole structure<ref>PMID: 21059682 </ref>. Altered side chain residues of posaconazole enhances its antifungal activity...(put specific sidechains here? Or in mechanisms?) | ||
== Function == | == Function == | ||
The primary component of Noxafil, posaconazole, is a broad-spectrum antifungal agent that has activity against Candida species, Aspergillus species, Cryptococcus neoformans, the zygomycetes, and other filamentous fungi. It is commonly used in immunocompromised patients or patients at high risk for fungal infections. | The primary component of Noxafil, posaconazole, is a broad-spectrum antifungal agent that has activity against Candida species, Aspergillus species, Cryptococcus neoformans, the zygomycetes, and other filamentous fungi. It is commonly used in immunocompromised patients or patients at high risk for fungal infections. Posaconazole | ||
==Mechanism== | ==Mechanism== | ||
| Line 20: | Line 20: | ||
==Pharmacology== | ==Pharmacology== | ||
== References == | == References == | ||
